Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Obesity/Overweight | Unmet Need | US/EU | 2019

Login to access report north_east
Contact sales account_box

Obesity is arguably the most pressing public health issue in the United States with its chronic progression that is associated with both type 2 diabetes and adverse cardiovascular health. Current therapies have struggled to achieve meaningful weight loss without compromising the overall risk-benefit of intervention. Following a series of high profile market withdrawals, the barren obesity drug landscape saw a relative rush of new treatment options come to market from 2012 to 2017. In this report, endocrinologists reveal how the current generation of antiobesity drugs compare with one another and what attributes the next generation of these agents will need to crack this medically important and potentially lucrative market.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for obesity?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for obesity?
  • What are the prevailing areas of unmet need and opportunity in obesity?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European endocrinologists for a hypothetical new obesity drug?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 U.S. and 30 European endocrinologists fielded in December 2018.

Key companies: Novo Nordisk, Eisai, Vivus, Orexigen Therapeutics, Pernix Therapeutics.

Key drugs: Saxenda, Qsymia, Contrave/Mysimba, Belviq.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east